pharmaceutical investing BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
